My professional life over five decades meandered from a high school ambition to be a psychiatrist and understand the "mind" to biochemical studies of neurotransmitters and drugs. Hopefully, the tale of my quirky impatient curiosity about "too many" different areas will be useful for young scientists embarking on their own careers.
My first professional interest was not in science but in psychiatry, based on a fascination with philosophy that began in high school. The summer before medical school I obtained a job at the National Institutes of Health (NIH), working on the metabolism of the amino acid histidine. I became hooked on research, spending all summers and elective periods in medical school at the NIH. Although still interested in clinical psychiatry, I was fortunate to obtain a research associate position at the NIH working with Julius Axelrod studying drugs and neurotransmitters. Julie was an extraordinary mentor, and I opted for a career in "molecular psychiatry." After the NIH, I went to Johns Hopkins for a psychiatry residency and then set up my laboratory and stayed. Other than summers in medical school, my sole scientific training comprised those 2 years in Julie's laboratory. By contrast, present-day young biomedical scientists typically spend 5-8 years in graduate school followed by two postdoctoral stints, each for half a dozen years. I fear that today's prolonged training may stifle innate creativity, and so I would advocate for shorter rather than longer training periods, regardless of worries about being properly prepared to get a job or an NIH grant. Today's young scientists worry that they need 5-6 years to publish a paper. With Julie, I published more than a half dozen full-length papers in respected journals in 2 years, which was not exceptional in those days.
When I set up my own laboratory at Johns Hopkins in 1966, I surveyed the world of molecular psychiatry. What path should I follow? Depression is the most common mental illness, afflicting roughly 10% of the world's population. The incidence of schizophrenia is only about 1%, but most individuals with schizophrenia face a life of profound disability and, typically, from their 20s are never again productive citizens. By contrast, most depressed patients function reasonably well so that the morbidity from schizophrenia is much greater. Moreover, the bizarre mental aberrations of schizophrenia pose fundamental questions about the nature of neuronal processes that underlie cognition and emotion. Despite the importance of mental illness, back then there were no reproducible findings of molecular abnormalities worth pursuing. Accordingly, instead of plunging ahead to study the brains of psychiatric patients, I heeded one of Julie's admonitions: "There are lots of important problems. Only attack those for which you can divine simple experiments with clear answers."
Instead of trying to solve the puzzle of schizophrenia, I chose a more modest goal, to learn more about neurotransmitters and how they mediate actions of psychoactive drugs. Early work in our lab focused upon neurotransmitter uptake into the nerves that released them, the system for neurotransmitter inactivation first enunciated by Axelrod. We developed a simple approach to monitor transmitter uptake in nerve terminals in a relatively high-throughput fashion (Coyle and Snyder, 1969) . During a visit to the Lilly Drug Company, I advocated the use of this screening procedure to differentiate drugs inhibiting the reuptake of neurotransmitters such as norepinephrine and serotonin. Lilly scientists subsequently used this approach to develop the first serotonin-selective uptake inhibitor fluoxetine (Prozac) (Kramer, 1993) .
My early years as an independent researcher convey lessons that may be relevant to today's young investigators. I embarked upon a research direction that was quite unlike the pineal gland research that had been my focus in Julie's laboratory. Doing something very different enabled me to establish my own psychological and professional identity. The work on drugs and neurotransmitter uptake depended on new methodology. In my experience, simple, sensitive, and specific assays are the royal road to data acquisition. Acquiring abundant data in turn makes for discovery. Too often, scientists slavishly follow methods cookbooks from the literature uncritically, when a few hours of critical, creative thinking could lead to new more efficient methods. Finally, I have always felt it is important to bear in mind the therapeutic relevance of basic research. The US Congress funds the NIH to discover causes of and cures for disease. Fundamental advances in knowledge, from the perspective of legislators, are merely byproducts. Never forget that, whether MD or PhD, we in the biomedical sciences are in the laboratory to help the sick.
In the early 1970s, much was known about biogenic amine neurotransmitter biosynthesis, metabolism, and transport. But at a molecular level little was known about neurotransmitter interactions with their receptors, the key feature of synaptic signaling. The national focus upon heroin abuse impelled my lab to enter the opiate field, leading to the identification of opiate receptors by the simple binding of radiolabeled opiates to crude brain membranes (Pert and Snyder, 1973) . This approach could be readily applied to all of the major neurotransmitters using tritiated drugs or the neurotransmitters themselves. The receptor binding techniques that we developed trapped
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Solomon H. Snyder 1, membranes on small filters in a vacuum manifold permitting experiments with hundreds of test tubes a day. This enabled us to evaluate large numbers of drugs and to seek molecular explanations for drug action. For instance, the relative potencies of antipsychotic neuroleptic drugs were shown to correlate with potencies in blocking a type of dopamine receptor, now designated D2. This fit with other evidence that the biogenic amine neurotransmitter dopamine is localized to neuronal systems that regulate cognition and emotions. Sedative-hypotensive influences of the drugs reflected affinity for the α-adrenergic subtype of receptor for norepinephrine, known to regulate blood pressure and alertness. Drug affinities for the muscarinic subtype of the acetylcholine receptor correlated inversely with extrapyramidal side effects that resemble those associated with the neurodegenerative disorder Parkinson's disease. Knowing the receptors that mediate therapeutic and adverse effects of drugs permitted the rational design of more potent and safer therapeutic agents. Using different ligands it was then possible to discriminate subtypes of serotonin receptors (molecular cloning has now differentiated 14) that mediate actions of diverse drugs ranging from antidepressants to anti-nausea agents.
When we identified opiate receptors, some of my senior colleagues advised me to drop everything else and focus exclusively upon opiate addiction because of its fundamental importance to society. But I had no idea how to discover the molecular bases of addiction. Instead, I used the lessons taught by our opiate receptor work to define diverse neurotransmitter receptors and drug influences. My prejudice is to focus on problems that can be realistically solved while never discarding ultimate ideals that may not yet be achievable.
As "man was not born with morphine in him," several groups including our own (Snyder, 1975) sought endogenous morphine-like substances leading to the elegant isolation by Hughes and Kosterlitz (Hughes et al., 1975) of the enkephalin pentapeptides. This work spawned studies identifying multiple peptides as neurotransmitters, a new chemical class in addition to biogenic amines and amino acid transmitters. The discovery in the late 1980s that a gas, nitric oxide (NO), occurs in biological tissues and mediates blood vessel regulation prompted investigations into NO as a neurotransmitter (Bredt and Snyder, 1994) . A neuron-specific form of NO synthase converts arginine to NO and citrulline, and NO-forming neurons abound in the brain. In the peripheral nervous system, NO is a major neurotransmitter mediating numerous functions including penile erection. NO isn't the only gasotransmitter. Carbon monoxide, formed from heme by heme oxygenase, also has transmitter properties (Boehning and Snyder, 2003) . Very recently, compelling evidence has emerged that hydrogen sulfide is a messenger molecule mediating endothelial-derived relaxing factor activity and mammalian blood pressure (Yang et al., 2008) .
The discovery of new neurotransmitters tells us much about how progress is made in the neurosciences and probably in most of the biological sciences.
When I was a medical student only two or three neurotransmitters were known. Most neurophysiologists felt that two would suffice, one for excitation and one for inhibition. The biogenic amines, such as dopamine, serotonin, and norepinephrine, account for a relatively small proportion of neurons in the brain. Amino acids such as glutamate and γ-aminobutyric acid (GABA) together involve 90% of brain synapses. Thus, when peptides were identified as neurotransmitters, many investigators felt that there wasn't enough "room" in the brain for them. The finding that every neuron contains several neurotransmitters helped to address this question. The subsequent identification of gases and D-amino acids, such as D-serine, as transmitters came as a big surprise. One central dogma of neurotransmission was that neurotransmitters must be stored in small synaptic vesicles and released by a unique process, "exocytosis," whereby the vesicles fuse with the membranes of the nerve endings. The gaseous neurotransmitters overturned this dogma as they cannot be locked up in vesicles. The gases overturned another "law" of neurotransmission, that all neurotransmitters must act upon "receptors," membrane proteins located on the external surface of adjacent cells. Not so for the gases, which merely diffuse into adjacent cells and, in the case of NO and hydrogen sulfide, chemically modify sulfhydryl groups of cysteines in target proteins. As for D-serine, it seemed to violate a central tenet of biology: D-sugar and L-amino acid stereospecificity. What does all of this teach us? Don't be satisfied with established catechism. Rules are made to be broken. Go where questions take you even if you find yourself disputing scientific authority.
Might research on drugs and neurotransmitters shed light on "causes" of mental illness (Table 1) ? Some drugs mimic psychosis impressively, suggesting that knowing their molecular mechanisms of action will shed light on aberrant transmission in the brains of psychiatric patients. Thus, cocaine and amphetamines, which facilitate actions of dopamine, elicit a paranoid psychosis that resembles features of acute paranoid schizophrenia. Conversely, antipsychotic neuroleptic drugs act by blocking D2 Relieves schizophrenic symptoms dopamine receptors and are thought to relieve fundamental symptoms of schizophrenia. These observations gave rise to the "dopamine hypothesis" of schizophrenia, positing that excess dopamine neurotransmission plays some role in the neuropathophysiology of the illness. An increase in D2 dopamine receptors has been reported in the brains of unmedicated schizophrenics, though these findings are controversial. There is better evidence that polymorphisms in the gene encoding the dopamine-metabolizing enzyme catechol O-methyltransferase (COMT) differentially mediate executive mental functions (Apud and Weinberger, 2007) . Normal individuals with a valine/ valine at amino acid 158 resulting in high COMT activity and hence less dopamine perform less well than individuals with methionine/methionine at amino acid 158. These findings predict that COMT inhibitors that can penetrate the brain may be therapeutic. The work on COMT illustrates a research strategy that commences with links between specific neurotransmitters and drugs that influence schizophrenia. It also demonstrates a powerful approach coordinating human genetics with behavioral studies in patients. The same research team recently carried out an even more ambitious effort linking schizophrenia to a specific potassium ion channel called KCNH2 (also called Herg) (Huffaker et al., 2009) . Whereas the COMT studies compared two enzyme isoforms that are universally expressed, the new study identified an isoform of KCNH2 that occurs only in primates and is derived by alternative splicing virtually exclusively in the brain where it is expressed at much higher levels than the native channel. There followed genetic analysis comparing several thousand schizophrenic patients with healthy individuals, which revealed an association of single-nucleotide polymorphisms in KCNH2 with schizophrenia. Individuals with these polymorphisms display cognitive abnormalities often associated with schizophrenia including lower IQ scores, slower cognitive processing, and even memory-associated abnormalities shown by functional MRI imaging. The hippocampus of postmortem schizophrenic patients displayed substantially greater levels of the mutant KCNH2 potassium channel than did the hippocampus of healthy individuals. Finally, the authors demonstrated neurophysiological differences in the mutant and wild-type ion channels, with the former inducing a rapidly deactivating potassium current and a high-frequency nonadapting neuronal firing pattern.
This potassium channel research illustrates some important concepts regarding a search for the "cause" of mental illness. Conventional genetic analysis would never have unearthed the unique alternatively spliced isoform of the KCNH2 channel. Single-nucleotide polymorphism research itself would have been only of modest interest because the disease-control differences were not enormous. The concatenation of findings from multiple venues led to a compelling case for the importance of this altered potassium ion channel in schizophrenia.
Another approach to unraveling the mysteries of schizophrenia involves glutamate, the principal excitatory neurotransmitter in the brain, which acts via its N-methyl-D-aspartate (NMDA) receptor. Phencyclidine (PCP), a widely used illicit drug, elicits a psychosis that is often indistinguishable from schizophrenia. PCP, widely regarded as the best drug model of schizophrenia, acts by blocking NMDA receptors. Conversely, in clinical trials, agents that activate the so-called glycine site of NMDA receptors-such as D-serine, D-cycloserine, and glycine itself-relieve the symptoms of schizophrenia. The NMDA receptor is "ionotropic," incorporating an ion channel that is permeable to sodium and calcium ions. Metabotropic neurotransmitter receptors are linked to G proteins and adenylyl cyclase or phospholipase C. Activation of metabotropic glutamate (mGluR) receptors, located on the nerve terminals of glutamate neurons, alters glutamate release. Recently, a drug (agonist) that stimulates the mGluR2 glutamate receptor has been shown to alleviate schizophrenic symptoms as effectively as the well-established antipsychotic drug olanzapine (Patil et al., 2007) .
But where to go next? This tale of drug-neurotransmitter research shows that one can make useful contributions even while failing to solve the socalled big question, "What causes schizophrenia, affective illness, and anxiety?" In pursuing my own career, might I have erred in not seeking these causes? Perhaps I was late in adopting the powerful techniques of molecular biology. Had I been more conversant with molecular genetics, perhaps I would have embarked on a search for genes underlying the major mental illnesses. I follow the literature of this field and am entranced with each new advance. Identifying mutations in the genes encoding amyloid precursor protein and presenilins in familial forms of Alzheimer's disease elegantly fits with abundant evidence for a role of the amyloid beta peptide in the much more frequent, sporadic forms of the illness. The discovery that mutations in DISC-1, a protein involved in axonal growth and neuronal positioning, are responsible for the schizophreniform and affective symptoms of several families with schizophrenia is tantalizing, as are reports of gene mutations that lead to autism (Chubb et al., 2008) . I have faith that genes conferring a susceptibility to these illnesses will be unraveled in the not-too-distant future.
But there are caveats. Elegant and exhaustive genetic linkage studies in schizophrenia and affective disorder appear to indicate that no single genetic abnormality will account for a major portion of the disease population (Psychiatric GWAS Consortium Coordinating Committee, 2009). Instead, very large numbers of rare mutations might conspire to influence disease development. In this case, it is hard to imagine how one could make use of the genetic data to link genes with brain dysfunction in the disease, to provide genetic counseling, and, most importantly, to develop genebased curative drugs.
Even in cases where we have definitive genetic data, its translation to an understanding of pathophysiology and therapy may not be simple. The specific mutation underlying Huntington's disease was reported in 1993 (The Huntington's Disease Collaborative Research Group, 1993) . The disease is caused by a mutation leading to large numbers of glutamine repeats in the ubiquitous protein huntingtin. Sixteen years later, we still don't know the normal function of huntingtin nor do we have definitive insight into why this protein, expressed uniformly throughout the brain and all over the body, predominantly damages a single part of the brain, the corpus striatum. Some insight into this question has come from recent protein binding studies showing that a striatal-specific small G protein, Rhes, interacts selectively with mutant huntingtin, SUMOylating it and disaggregating the mutant huntingtin protein resulting in cytotoxicity (Subramaniam et al., 2009) . Drugs that block the binding of Rhes to mutant huntingtin might delay or even prevent the onset of brain damage.
Where is the field of molecular psychiatry going? Molecular genetic studies of the major mental illnesses are becoming increasingly sophisticated. The possibility that there will be no single genes underlying major forms of the diseases is disconcerting. I suspect that the "answers" may evolve in unexpected venues. For instance, the KCNH2 potassium ion channel story dealt with a gene that would not normally be linked strongly to schizophrenia if one used the conventional methodology of examining genes in peripheral white blood cells. Instead, brain-specific alternative splicing was the key event. Perhaps further exploration will reveal a multitude of such brain-specific molecular aberrations.
Using drugs as the starting point for finding disease abnormalities may bear fruit. Psychopharmacology offers the potential of major pay-offs long before one finds "causes" of disease. The conventional antipsychotic drugs have been of immense benefit whether or not their action by blocking dopamine receptors tells us anything about schizophrenia. Research on dopamine provoked by the drug actions led to insights into dopamine as an important neurotransmitter of cognitive functions mediated by the prefrontal area of the cerebral cortex, which has been implicated in the cognitive disturbances of schizophrenia. This work also led to the discovery of cognitive abnormalities associated with polymorphisms in COMT, the enzyme that metabolizes dopamine. New evidence showing that drugs that stimulate a glutamate receptor subtype are as effective as earlier antipsychotic drugs will likely lead to a further escalation of research into glutamate as a critical neurotransmitter in schizophrenia. In addressing these questions, I expect that largescale collaborative studies incorporating molecular, neurophysiological, genetic, and behavioral research will become more prevalent.
I have no surefire answers for young researchers seeking the "answer" to mental illness. One line of advice would be to heed advances in basic and clinical molecular genetics. However, I would eschew a direct "fullback" attack to find the culprit gene. Instead, I might advocate the behavior of a "wide receiver," taking advantage of clues from multiple seemingly unrelated sources, such as cancer, cardiovascular, and immunology research. The best insights often come from free-floating associations, which bring to bear on your problem what may seem to be "far out" sources. Most importantly, the new ideas should be testable in very simple experiments. Always design your experiments to ensure that whatever you find will be useful whether or not it solves the big question. Finally, don't plan your research to fit the supposed dictates of funding agencies-I've never done the experiments proposed in any of my grant applications. Good luck!
